Table 2.

Summary of clinical efficacy

	Lapatinib plus bevacizumab
	(N = 52)
PFS rate at week 12
Patients reaching week 12 without PD n (%)	36 (69)
Crude 12-week PFS rate, % (95% CI)	69.2 (54.9, 81.3)
ORR
CR or PR confirmed, % (95% CI)	13.3 (5.1, 26.8)
CBR
CR or PR or SD ≥24 weeks, % (95% CI)	30.8 (18.7, 45.1)
Overall PFS
Progressions n (%)	27 (52)
Censoreda n (%)	25 (48)
Median PFS, weeks, % (95% CI)	24.7 (20.4, 35.1)

PFS progression-free survival, PD progressive disease, CI confidence interval, ORR overall response rate, CR complete response, PR partial response, CBR clinical benefit rate, SD stable disease

^aPatients who did not die or progress until the clinical cutoff for these data (July 22, 2008)